Anacor Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA for the Treatment of Mild-to-Moderate Atopic Dermatitis With AN2728

[at noodls] – PALO ALTO, Calif.–(BUSINESS WIRE)– Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has successfully completed an End-of-Phase 2 meeting with the United States Food and Drug Administration … more

View todays social media effects on ANAC

View the latest stocks trending across Twitter. Click to view dashboard

See who Anacor is hiring next, click here to view